Author

Luíz Leite

Observed name: Luiz Leite

ORCID: 0000-0001-6324-7797

Observed ORCID: 0000-0001-6324-7797

OpenAlex ID: A5102720403

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry

2017 · David Fiorentino, Vincent Ho, et al. · Journal of the American Academy of Dermatology · 164

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

2021 · Tiago Torres, Luis Puig, et al. · American Journal of Clinical Dermatology · 127

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study

2022 · Tiago Torres, Luis Puig, et al. · American Journal of Clinical Dermatology · 84

Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study

2019 · Tiago Torres, Anna Balato, et al. · Journal of the American Academy of Dermatology · 52

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study

2019 · Andrea Chiricozzi, Anna Balato, et al. · Journal of Dermatological Treatment · 43

THERAPEUTIC HOTLINE: Treatment of pityriasis rubra pilaris with etanercept

2011 · Rita Guedes, Luiz Leite · Dermatologic Therapy · 21

Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab

2017 · Inês Raposo, Cláudia Carvalho, et al. · European Journal of Dermatology · 17

Age affects drug survival rates of interleukin ( IL )‐17 and IL ‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study

2024 · Andrea Chiricozzi, Giulia Coscarella, et al. · Journal of the European Academy of Dermatology and Venereology · 16

Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis

2019 · Inês Raposo, Andreia Bettencourt, et al. · Acta Médica Portuguesa · 12

Portuguese Position Paper on the Use of Biosimilars in Psoriasis

2016 · Tiago Torres, Ana Ferreira, et al. · Acta Médica Portuguesa · 12

Real-World Evidence on Dose Spacing of Risankizumab for Psoriasis: A Multicenter Retrospective Cohort Study

2025 · Martim Luz, Ana Luísa João, et al. · Dermatology and Therapy · 6

Real‐World Effectiveness, Safety and Drug Survival of Tildrakizumab in Adult Patients With Plaque Psoriasis: A 2‐Year Portuguese Multicenter Retrospective Cohort Study

2025 · Tiago Torres, Barbara Vieira Granja, et al. · International Journal of Dermatology · 4

Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort Study

2025 · Tiago Torres, Ana Luísa João, et al. · American Journal of Clinical Dermatology · 4

Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study

2025 · Marco Sousa, Ana Luísa João, et al. · BioDrugs · 2

Works count: 14

Citation count: 564

H-index: 10

I10-index: 10